Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHXGet Free Report) in a report issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

NASDAQ ATHX opened at $0.00 on Tuesday. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99. The company has a market capitalization of $191,328.90, a P/E ratio of 0.00 and a beta of -0.90.

About Athersys

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Recommended Stories

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.